{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:30Z","timestamp":1772119590686,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10557-021-07295-8","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T04:02:32Z","timestamp":1637380952000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Calcium Channel Blockers on Aspirin Reactivity in Patients with Coronary Artery Disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Afek","family":"Kodesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Lev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorit","family":"Leshem-Lev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Solodky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Kornowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-7937","authenticated-orcid":false,"given":"Leor","family":"Perl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"key":"7295_CR1","doi-asserted-by":"crossref","unstructured":"Varga-Szabo D, BRAUN A, NIESWANDT B. Calcium signaling in platelets. J Thromb Haemost. 2009;7:1057\u201366.","DOI":"10.1111\/j.1538-7836.2009.03455.x"},{"key":"7295_CR2","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1073\/pnas.76.4.1653","volume":"76","author":"DR Hathaway","year":"1979","unstructured":"Hathaway DR, Adelstein RS. Human platelet myosin light chain kinase requires the calcium-binding protein calmodulin for activity. Proc Natl Acad Sci U S A. 1979;76:1653\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7295_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S0021-9258(19)75739-1","volume":"262","author":"S Shattil","year":"1986","unstructured":"Shattil S, Brasso L. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1986;262:992\u20131000.","journal-title":"J Biol Chem"},{"key":"7295_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12265-013-9529-1","volume":"7","author":"P Fontana","year":"2013","unstructured":"Fontana P, Zufferey A, Daali Y, Reny J. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res. 2013;7:29\u201338.","journal-title":"J Cardiovasc Transl Res"},{"key":"7295_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1941875210395776","volume":"1","author":"K Schwartz","year":"2011","unstructured":"Schwartz K. Aspirin resistance a clinical review focused on the most common cause, noncompliance. The Neurohospitalist. 2011;1:94\u2013103.","journal-title":"The Neurohospitalist."},{"key":"7295_CR6","doi-asserted-by":"crossref","unstructured":"Shiyovich A, Sasson L, Lev E, Solodky A, Kornowski R, Perl L. The association between multi-vessel coronary artery disease and high on-aspirin platelet reactivity. Cardiovasc Drugs Ther. 2021;","DOI":"10.1007\/s10557-021-07195-x"},{"key":"7295_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0167-5273(97)00248-9","volume":"62","author":"JD Folts","year":"1997","unstructured":"Folts JD. Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin. Int J Cardiol. 1997;62:111\u20137.","journal-title":"Int J Cardiol"},{"key":"7295_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0049-3848(88)90199-5","volume":"50","author":"JD Folts","year":"1988","unstructured":"Folts JD, Rowe GG. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res. 1988;50:507\u201316.","journal-title":"Thromb Res"},{"key":"7295_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.phrs.2013.04.010","volume":"74","author":"K Karolczak","year":"2013","unstructured":"Karolczak K, Kamysz W, Karafova A, Drzewoski J, Watala C. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. Pharmacol Res. 2013;74:7\u201322.","journal-title":"Pharmacol Res"},{"key":"7295_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/FJC.0000000000000240","volume":"66","author":"M Verdoia","year":"2015","unstructured":"Verdoia M, Schaffer A, Pergolini P, Rolla R, Barbieri L, Bellomo G, et al. Homocysteine levels influence platelet reactivity in coronary artery disease patients treated with acetylsalicylic acid. J Cardiovasc Pharmacol Ther. 2015;66:35\u201340.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"7295_CR11","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.amjcard.2020.12.018","volume":"144","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Badimon J. Overview of aspirin and platelet biology. Am J Cardiol. 2021;144:S2-9.","journal-title":"Am J Cardiol"},{"key":"7295_CR12","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/archinte.1989.00390070171030","volume":"149","author":"AE Skolnick","year":"1989","unstructured":"Skolnick AE, Frishman WH. Calcium channel blockers in myocardial infarction. JAMA Intern Med. 1989;149:1669\u201377.","journal-title":"JAMA Intern Med"},{"key":"7295_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/eurheartj\/14.suppl_F.18","volume":"4","author":"PH Held","year":"1993","unstructured":"Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J. 1993;4:18\u201325.","journal-title":"Eur Heart J"},{"key":"7295_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1136\/bmj.299.6709.1187","volume":"299","author":"PH Held","year":"1989","unstructured":"Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989;299:1187\u201392.","journal-title":"BMJ"},{"key":"7295_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","volume":"124","author":"MJ Price","year":"2011","unstructured":"Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124:1132\u20137.","journal-title":"Circulation"},{"key":"7295_CR16","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","volume":"56","author":"G Campo","year":"2010","unstructured":"Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T\/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010;56:1447\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"7295_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/hrt.2009.171488","volume":"96","author":"T Gremmel","year":"2010","unstructured":"Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart. 2010;96:186\u20139.","journal-title":"Heart"},{"key":"7295_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1755-5922.12138","volume":"33","author":"T Gremmel","year":"2015","unstructured":"Gremmel T, Durstburger M, Eichelberger B, Koppensteiner R, Panzer S. Calcium-channel blockers attenuate the antiplatelet effect of clopidogrel. Cardiovasc Ther. 2015;33:264\u20139.","journal-title":"Cardiovasc Ther"},{"key":"7295_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s002280050706","volume":"55","author":"M Katoh","year":"2000","unstructured":"Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55:843\u201352.","journal-title":"Eur J Clin Pharmacol"},{"key":"7295_CR20","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1021\/jm00110a012","volume":"34","author":"FP Guengerich","year":"1991","unstructured":"Guengerich FP, Brian WR, Iwasaki M, Sari MA, B\u00e4\u00e4rnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991;34:1838\u201344.","journal-title":"J Med Chem"},{"key":"7295_CR21","doi-asserted-by":"crossref","unstructured":"Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, et al. Clopidogrel pharmacogenetics. Circ Cardiovasc Interv. 2019;12.","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811"},{"key":"7295_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1160\/TH09-08-0516","volume":"103","author":"AM Harmsze","year":"2010","unstructured":"Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost. 2010;103:920\u20135.","journal-title":"Thromb Haemost"},{"key":"7295_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/fcp.12219","volume":"30","author":"N Marsousi","year":"2016","unstructured":"Marsousi N, Doffey-Lazeyras F, Rudaz S, Desmuelas JA, Daali Y. Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells. Fundam Clin Pharmacol. 2016;30:577\u201384.","journal-title":"Fundam Clin Pharmacol"},{"key":"7295_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/molecules23020455","volume":"23","author":"Z Sun","year":"2018","unstructured":"Sun Z, Wu Y, Yang B, Zhu B, Hu S, Lu Y, et al. Inhibitory influence of Panax notoginseng saponins on aspirin hydrolysis in human intestinal Caco-2 cells. Molecules. 2018;23:455.","journal-title":"Molecules"},{"key":"7295_CR25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1159\/000354497","volume":"32","author":"M Kugai","year":"2013","unstructured":"Kugai M, Uchiyama K, Tsuji T, Yoriki H, Fukui A, Qin Y, et al. MDR1 is related to intestinal epithelial injury induced by acetylsalicylic acid. Cell Physiol Biochem. 2013;32:942\u201350.","journal-title":"Cell Physiol Biochem"},{"key":"7295_CR26","first-page":"625","volume":"51","author":"ML Guarino","year":"2020","unstructured":"Guarino ML, Massimi I, Alemanno L, Conti L, Angiolillo DJ, Pulcinelli FM. MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation. J Thromb Haemost. 2020;51:625\u201332.","journal-title":"J Thromb Haemost"},{"key":"7295_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1055\/s-0038-1629920","volume":"118","author":"L Alemanno","year":"2018","unstructured":"Alemanno L, Massimi I, Klaus V, Guarino ML, Maltese T, Frati L, et al. Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity. Thromb Haemost. 2018;118:490\u2013501.","journal-title":"Thromb Haemost"},{"key":"7295_CR28","doi-asserted-by":"crossref","unstructured":"Borgognone A, Pulcinelli FM. Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport. Thromb Haemost. 108:955\u201362.","DOI":"10.1160\/TH12-04-0232"},{"key":"7295_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.RES.66.1.185","volume":"66","author":"OR Etingen","year":"1990","unstructured":"Etingen OR, Hajjar DP. Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. Circ Res. 1990;66:185\u201390.","journal-title":"Circ Res"},{"key":"7295_CR30","first-page":"117","volume":"52","author":"JB Simon","year":"1979","unstructured":"Simon JB. Studies on cholesterol ester formation and hydrolysis in liver disease: a selective review. Yale J Biol Med. 1979;52:117\u201326.","journal-title":"Yale J Biol Med"},{"key":"7295_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2165\/00003088-198510020-00004","volume":"10","author":"CJ Needs","year":"1985","unstructured":"Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmocokinetics. 1985;10:164\u201377.","journal-title":"Clin Pharmocokinetics."},{"key":"7295_CR32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1542\/peds.62.5S.867","volume":"62","author":"G Levy","year":"1978","unstructured":"Levy G. Clinical pharmacokinetics of aspirin. Pediatrics. 1978;62:867\u201372.","journal-title":"Pediatrics"},{"key":"7295_CR33","doi-asserted-by":"publisher","first-page":"B158","DOI":"10.1016\/0002-9149(85)90626-5","volume":"55","author":"JL Mehta","year":"1985","unstructured":"Mehta JL. Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism. Am J Cardiol. 1985;55:B158\u201364.","journal-title":"Am J Cardiol"},{"key":"7295_CR34","first-page":"33","volume":"1","author":"H Tallima","year":"2017","unstructured":"Tallima H, El Ridi R. Arachidonic acid: physiological roles and potential health benefits \u2013 a review. J Adv Res. 2017;1:33\u201341.","journal-title":"J Adv Res"},{"key":"7295_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-4939-8597-5_12","volume":"1816","author":"M Urooj Zafar","year":"2018","unstructured":"Urooj Zafar M, Santos-Gallego CG, Badimon L, Badimon JJ. Badimon perfusion chamber: an ex vivo model of thrombosis. Methods Mol Biol. 2018;1816:161\u201371.","journal-title":"Methods Mol Biol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07295-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T03:18:43Z","timestamp":1652152723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["7295"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07295-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-932481\/v1","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,20]]},"assertion":[{"value":"13 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}